Showing 6371-6380 of 8697 results for "".
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Hyperhidrosis May Up Risk for Anxiety, Depression and ADDhttps://practicaldermatology.com/news/hyperhidrosis-may-up-risk-for-anxiety-depression-and-add/2459877/Individuals with hyperhidrosis are more to have anxiety, depression and attention deficit disorder, according to new research presented at the American Academy of Dermatology’s (AAD) 2019 Annual Meeting in Washington. Of the 500 hyperhidrosis patients involved in the study, 13.8 p
- Study: Isotretinoin Does Not Raise Depression Riskhttps://practicaldermatology.com/news/study-isotretinoin-does-not-raise-depression-risk/2459878/Isotretinoin is not an independent risk factor for depression in adult acne patients, finds new research presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington. “There has been mixed evidence and much debate around the impact of isotretinoin on mo
- Regenerative Medicine Breakthrough: Mobile Bedside Bioprinter May Heal Woundshttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-mobile-bedside-bioprinter-may-heal-wounds/2459876/Researchers have created a mobile skin bioprinting system that allows bi-layered skin to be printed directly into a wound. The team demonstrated proof-of-concept of the system by printing skin directly onto pre-clinical models, and the next step is to conduct a clinical trial in humans, t
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Mustela Introduces Skin-Soothing PJs for Eczema-Prone Babies and Toddlershttps://practicaldermatology.com/news/mustela-introduces-skin-soothing-pjs-for-eczema-prone-babies-and-toddlers/2459885/The Global Wellness Institute recently cited smart and healing fashion as one of the biggest trends in wellness, and the new Mustela
- Sentient Lasers Unveils Dot Demo Servicehttps://practicaldermatology.com/news/sentient-lasers-unveils-dot-demo-service/2459886/Sentient Lasers has launched its new,
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&
- Physician Burnout Rates Fall Modestlyhttps://practicaldermatology.com/news/physician-burnout-rates-fall-modestly/2459892/The burnout rate among physicians in the United States has dropped, but there remains significant room for improvement, new data suggest. The burnout rate dropped modestly in 2017 from its peak in 2014. Current burnout rates are in line with 2011 levels. The triennial s